Novel antibody–drug conjugates for triple negative breast cancer by Aiko Nagayama, Neelima Vidula, Leif Ellisen, Aditya Bardia

Get full text

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer by Jamie O. Brett, Laura M. Spring, Aditya Bardia, Seth A. Wander

Get full text

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer by Fatima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia

Get full text

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging... by Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia

Get full text

Spinal intradural extraosseous Ewing’s sarcoma by Daniel Lachance, Jan Buckner, Michael Haddock, Aminah Jatoi, Aditya Bardia, Aziza Nassar, Farrah Mateen

Get full text

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer by Sheheryar Kabraji, Xavier Solé, Ying Huang, Clyde Bango, Michaela Bowden, Aditya Bardia, Dennis Sgroi, Massimo Loda, Sridhar Ramaswamy

Get full text

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer by Neelima Vidula, Andrzej Niemierko, Katherine Hesler, Lianne Ryan, Beverly Moy, Steven Isakoff, Leif Ellisen, Dejan Juric, Aditya Bardia

Get full text

Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer by Yael Bar, Jennifer C. Keenan, Andrzej Niemierko, Arielle J. Medford, Steven J. Isakoff, Leif W. Ellisen, Aditya Bardia, Neelima Vidula

Get full text

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer by Shannon McLaughlin, Erika Nakajima, Yael Bar, Jennifer A. Hutchinson, Jennifer Shin, Beverly Moy, Steven J. Isakoff, Aditya Bardia, Irene Kuter, Laura M. Spring

Get full text

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer by Anne Marie McCarthy, Nitya Pradeep Kumar, Wei He, Susan Regan, Michaela Welch, Beverly Moy, A. John Iafrate, Andrew T. Chan, Aditya Bardia, Katrina Armstrong

Get full text

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney

Get full text

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney

Get full text

Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison by Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. Fasching

Get full text

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer by Aditya Bardia, Javier Cortes, Sara A. Hurvitz, Suzette Delaloge, Hiroji Iwata, Zhi-Ming Shao, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Joyce O’Shaughnessy

Get full text

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer by Neelima Vidula, Andrew Lipman, Shumei Kato, Caroline Weipert, Katherine Hesler, Georges Azzi, Ahmed Elkhanany, Dejan Juric, Estelamari Rodriguez, Colleen Faulkner, Paul Makhlouf, Kristin Price, Joyce O’Shaughnessy, Aditya Bardia

Get full text

A careful reassessment of anthracycline use in curable breast cancer by Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon

Get full text

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f... by Nadia Harbeck, Fabio Franke, Rafael Villanueva-Vazquez, Yen-Shen Lu, Debu Tripathy, Louis Chow, Govind K Babu, Young-Hyuck Im, David Chandiwana, Anil Gaur, Brad Lanoue, Karen Rodriguez-Lorenc, Aditya Bardia

Get full text

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer by Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia

Get full text

Relationship of established risk factors with breast cancer subtypes by Anne Marie McCarthy, Tara Friebel‐Klingner, Sarah Ehsan, Wei He, Michaela Welch, Jinbo Chen, Despina Kontos, Susan M. Domchek, Emily F. Conant, Alan Semine, Kevin Hughes, Aditya Bardia, Constance Lehman, Katrina Armstrong

Get full text

TRK inhibitor in a patient with metastatic triple-negative breast cancer and fusions identified cell-free DNA analysis by Arielle J. Medford, Lauren Oshry, Baris Boyraz, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Charles S. Dai, Tasos Gogakos, Jennifer C. Keenan, Rachel H. Occhiogrosso, Phoebe Ryan, Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia

Get full text